Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
Year: 2020
Type: article
Study design: Clinical Trial
Abstract: Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (ER) –positive breast cancer. To study this treatment option, responses to three AIs were compared in a randomized phase II neoadjuvant trial designed to select agents for phase III investigations.
DOI: 10.17615/3dn4-1854
Authors: Babiera, Gildy V., Esserman, Laura J., Margenthaler, Julie, Guenther, Joseph M., DeSchryver, Katherine, Hunt, Kelly, Prat, Aleix, Olson, John A., Luo, Jingqin, Allred, D. Craig, Suman, Vera J., Hoog, Jeremy, Parker, Joel S., Snider, Jacqueline, Lin, Li, Leitch, Marilyn, Unzeitig, Gary W., Watson, Mark A., Ellis, Matthew J., Marcom, P. Kelly
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
Award: G3496640527
OpenAlex ID: W4299541504